Patent ID: 11891614
Assignee: CELLECTIS
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 11:
12. A method of preparing engineered T-cells for immunotherapy comprising
(a) inactivating PDCD1 in the T-cells comprising introducing into the T-cells by electroporation of RNAs encoding at least two half Transcription activator-like effector nucleases (TALE-nucleases) able to selectively inactivate by DNA cleavage a gene encoding PDCD1, to produce engineered T-cells; and
(b) expanding said engineered T-cells,
wherein said at least two half TALE-nucleases recognize and cleave a target sequence selected from SEQ ID NO:77 and SEQ ID NO:78,
wherein said at least two half TALE-nucleases are constituted by a first half-TALE nuclease and a second half-TALE nuclease; and
wherein the first half-TALE nuclease or the second half-TALE nuclease comprises the amino acid sequence encoded by a nucleic acid sequence selected from the group consisting of SEQ ID NO:95, SEQ ID NO:96, SEQ ID NO:97, and SEQ ID NO:98.